Overview

Description

  • NatureSynthetic
  • Amino Acid Sequence
    • SpeciesHuman

Associated products

Specifications

Our Abpromise guarantee covers the use of ab41843 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activity

    Blocking the activity of Anti-XIAP antibody (ab21278)

  • Applications

    Blocking - Blocking peptide for Anti-XIAP antibody (ab21278)

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: 0.02% Sodium Azide
    Constituents: 0.1% BSA, PBS, pH 7.2

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • AP 13
    • API3
    • Apoptosis Inhibitor 3
    • Baculoviral IAP repeat containing 4
    • Baculoviral IAP Repeat Containing Protein 4
    • Baculoviral IAP repeat-containing protein 4
    • BIRC 4
    • BIRC4
    • E3 ubiquitin-protein ligase XIAP
    • hIAP-3
    • hIAP3
    • HILP
    • IAP 3
    • IAP like protein
    • IAP-3
    • IAP-like protein
    • IAP3
    • ILP
    • ILP 1
    • ILP1
    • Inhibitor of apoptosis protein 3
    • Inhibitor of Apoptosis X Linked
    • Mammalian IAP Homologue A
    • MIHA
    • X linked IAP
    • X linked inhibitor of apoptosis
    • X linked inhibitor of apoptosis E3 ubiquitin protein ligase
    • X linked inhibitor of apoptosis protein
    • X-linked IAP
    • X-linked inhibitor of apoptosis protein
    • Xiap
    • XIAP_HUMAN
    • XLP2
    see all
  • FunctionApoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
  • Tissue specificityUbiquitous, except peripheral blood leukocytes.
  • Involvement in diseaseDefects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
  • Sequence similaritiesBelongs to the IAP family.
    Contains 3 BIR repeats.
    Contains 1 RING-type zinc finger.
  • DomainThe first BIR domain is involved in interaction with TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.
  • Post-translational
    modifications
    Ubiquitinated and degraded by the proteasome in apoptotic cells.
    Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.
  • Cellular localizationCytoplasm.
  • Information by UniProt

References for Active human XIAP peptide (ab41843)

ab41843 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab41843.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"